Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis.
Open Access
- 1 February 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 142 (3) , 954-958
- https://doi.org/10.4049/jimmunol.142.3.954
Abstract
Toxoplasma gondii is an important cause of disease of the central nervous system in patients with AIDS. Among the variety of immunologic disorders encountered by AIDS patients is a depletion of CD4+ subpopulation of lymphocytes. In order to determine the role of this population of T lymphocytes in the generation of toxoplasmic encephalitis, mice chronically infected with T. gondii were treated with mAb GK1.5 directed against the cell surface glycoprotein L3T4 (CD4) of T lymphocytes. Histopathologic sections of brains of control and treated animals were examined at regular intervals during and after completion of treatment. The results demonstrated significantly less inflammation in brains of mice during treatment with GK1.5 mAb. In addition, recrudescence of the inflammatory process occurred after discontinuation of treatment. Similar results were observed in experiments in which different strains of mice and T. gondii were used.This publication has 2 references indexed in Scilit:
- Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic ConsiderationsAnnals of Internal Medicine, 1984
- Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.The Journal of Immunology, 1983